Interestingly, clinically-relevant genomic alterations of PIK3CA have been reported in some recurrent, metastatic cSCC [57] and PIK3CA activating mutations have been detected in some cSCC lymph node metastases [58]. This evidence concerns the gene PIK3CA and metastatic malignant neoplasm in the lymph nodes.